255 completed, 50 terminated, 41 recruiting, 26 unknown. 200 Phase 2, 152 Phase 1, 93 Phase 3, 7 Not applicable, 6 Early Phase 1.
Follow Topotecan: new trials by email Literature Review of Topotecan trials Research Report on Topotecan
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography - Recurrent Ganglioneuroblastoma, Recurrent Neuroblastoma | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 76 | 2027-06-25 | 2026-10-22 |
| The Safety and Efficacy of Intravitreal Topotecan for the Treatment of Proliferative Vitreoretinopathy Topotecan - Proliferative Vitreoretinopathy, Proliferative Vitreo-Retinopathy | Phase 1 | Not yet recruiting | Massachusetts Eye and Ear Infirmary | 50 | 2026-12-01 | 2026-10-16 |
| JSKN033 Versus Investigator's Choice of Chemotherapy in Recurrent or Metastatic Cervical Cancer JSKN033, Docetaxel, Topotecan - Recurrent or Metastatic Cervical Cancer | Phase 3 | Not yet recruiting | Jiangsu Alphamab Biopharmaceuticals Co., Ltd | 368 | 2026-09-01 | 2026-09-01 |
| A Study of SYS6043 in Platinum-Resistant, Advanced Ovarian, Primary Peritoneal, or Fallopian Tube Cancers SYS6043, Liposomal doxorubicin, paclitaxel, or topotecan - Platinum-resistant Ovarian Cancer, Platinum-resistant Primary Peritoneal Cancer | Phase 3 | Recruiting | CSPC Megalith Biopharmaceutical Co.,Ltd. | 460 | 2026-07-15 | 2026-09-23 |
| A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer ABBV-706, Topotecan, Lurbinectedin - Small Cell Lung Cancer | Phase 3 | Recruiting | AbbVie | 531 | 2026-07-02 | 2026-09-23 |
| A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer BL-M07D1, Liposomal Doxorubicin, Paclitaxel - Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 3 | Not yet recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 404 | 2026-07-01 | 2026-06-29 |
| An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China Rina-S, Paclitaxel, Topotecan - Platinum-resistant Ovarian Cancer | Phase 3 | Recruiting | Genmab | 82 | 2026-06-26 | 2026-10-06 |
| A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01) Mocertatug rezetecan, Paclitaxel, Pegylated liposomal doxorubicin (PLD) - Ovarian Neoplasms | Phase 3 | Recruiting | GlaxoSmithKline | 450 | 2026-06-18 | 2026-10-15 |
| Chronic CED of TPT for Recurrent Malignant Glioma Topotecan - Brain Tumor, Recurrent, Malignant Glioma (WHO Grade III or IV) | Phase 1 | Recruiting | Jeffrey N. Bruce | 6 | 2026-06-12 | 2026-06-15 |
| Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma Eflornithine, Topotecan, Cyclophosphamide - Osteosarcoma, Ewing Sarcoma | Phase 2 | Recruiting | Milton S. Hershey Medical Center | 406 | 2026-06-05 | 2026-10-06 |
| Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer NMS-03305293, Topotecan - Ovarian Cancer | Phase 1 | Recruiting | Nerviano Medical Sciences | 24 | 2026-05-13 | 2026-05-28 |
| A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer SHR-A2102 for Injection, Pemetrexed Disodium for Injection, Gemcitabine Hydrochloride for Injection - Recurrent Cervical Cancer, Metastatic Cervical Cancer | Phase 3 | Recruiting | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | 398 | 2026-03-30 | 2026-04-06 |
| Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes Vincristine, Doxorubicin, Cyclophosphamide - Metastatic Ewing Sarcoma | Phase 1 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 15 | 2026-02-05 | 2026-09-25 |
| An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing Serplulimab, Fluzoparib, Topotecan/Irinotecan/Paclitaxel/Temozolomide - SCLC, Extensive Stage | Phase 1 / Phase 2 | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 100 | 2025-12-31 | 2025-08-26 |
| AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer AZD5335, Mirvetuximab Soravtansine (MIRV), Paclitaxel - Epithelial Ovarian Cancer | Phase 3 | Recruiting | AstraZeneca | 1100 | 2025-12-29 | 2026-07-21 |
| Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer ZG006, Topotecan - Small-cell Lung Cancer | Phase 3 | Recruiting | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 420 | 2025-12-12 | 2026-01-05 |
| Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression INCB123667, Investigator's choice of chemotherapy - Ovarian Cancer | Phase 3 | Recruiting | Incyte Corporation | 466 | 2025-12-09 | 2026-10-15 |
| A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer Sofetabart Mipitecan, Paclitaxel, Topotecan - Ovarian Neoplasms, Fallopian Tube Neoplasms | Phase 3 | Recruiting | Eli Lilly and Company | 1630 | 2025-10-22 | 2026-10-08 |
| A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) [EMBOLD SCLC-301] Risvutatug rezetecan (Ris-Rez), Topotecan - Neoplasms, Lung | Phase 3 | Recruiting | GlaxoSmithKline | 420 | 2025-08-11 | 2026-10-20 |
| A Study Comparing BL-B01D1 With the Investigator's Choice of Chemotherapy in Patients With Platinum-resistant Recurrent Epithelial Ovarian Cancer(PANKU-GYN01) BL-B01D1, Liposomal doxorubicin, Paclitaxel or Topotecan - Epithelial Ovarian Cancer, Fallopian Tube Cancer | Phase 3 | Recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 450 | 2025-08-04 | 2026-07-07 |
Showing 20 of 420. Sign in to see all of them.
Ovarian Neoplasms (94) · Small Cell Lung Carcinoma (77) · Neuroblastoma (44) · Carcinoma, Ovarian Epithelial (43) · Fallopian Tube Neoplasms (42) · Lung Neoplasms (40) · Neoplasms (29) · Uterine Cervical Neoplasms (27) · Leukemia (20) · Brain Neoplasms (18) · Leukemia, Myeloid, Acute (17) · Recurrence (17) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (15) · Sarcoma (15) · Neoplasm Metastasis (13)
National Cancer Institute (NCI) (40) · GlaxoSmithKline (25) · Children's Oncology Group (16) · St. Jude Children's Research Hospital (13) · Gynecologic Oncology Group (12) · H. Lee Moffitt Cancer Center and Research Institute (11) · SCRI Development Innovations, LLC (11) · Alliance for Clinical Trials in Oncology (9) · Case Comprehensive Cancer Center (7) · M.D. Anderson Cancer Center (7) · Memorial Sloan Kettering Cancer Center (7) · Mayo Clinic (6) · NYU Langone Health (6) · City of Hope Medical Center (5) · Fox Chase Cancer Center (5)
United States (296) · Canada (67) · France (49) · Spain (48) · Germany (47) · China (43) · Italy (43) · United Kingdom (43) · Australia (41) · Belgium (37) · South Korea (35) · Poland (30) · Netherlands (28) · Hungary (24) · Switzerland (23)
Howard S. Hochster, MD (6) · Anthony Greco, MD (4) · Brenda W. Cooper, MD (3) · Howard A. Burris, MD (3) · Jalid Sehouli (3) · James R. Jett, MD (3) · Jeffrey Bruce, MD (3) · Nathan Levitan, MD (3) · Amar Gajjar, MD (2) · Amy D. Tiersten, MD (2) · Anish Thomas, M.D. (2)
PMID 37407274, PMID 37185961, PMID 42820295, PMID 16882940, PMID 19427025, PMID 31401903, PMID 34028986, PMID 10655437, PMID 10882162, PMID 11165136, PMID 11304695, PMID 11479630, PMID 11896112, PMID 12165894, PMID 12880954, PMID 14534883, PMID 14586216, PMID 14766258, PMID 14970858, PMID 15013589, PMID 15145163, PMID 15911864, PMID 15911865, PMID 15975641, PMID 16129365, PMID 16150481, PMID 16158312, PMID 16216315, PMID 16382125, PMID 16412499, PMID 16435380, PMID 16631245, PMID 16755177, PMID 16912194, PMID 16966261, PMID 17336213, PMID 17409859, PMID 17409984, PMID 17513814, PMID 17607121, PMID 18096059, PMID 18191187, PMID 18447671, PMID 18538834, PMID 18621625, PMID 18977518, PMID 18978345, PMID 19238149, PMID 19307014, PMID 19648970
U10CA180886 (10), U10CA098543 (8), U10CA027469 (6), U10CA180868 (6), 2025 (5), 2023 (4), P30CA043703 (4), U10CA031946 (4), 2009 (3), 2016 (3), P30CA015083 (3), P30CA033572 (3), U01CA069912 (3), 2008 (2), 2015 (2)